Achmea Investment Management B.V. Sells 996 Shares of Eli Lilly and Company (NYSE:LLY)

Achmea Investment Management B.V. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 58,850 shares of the company’s stock after selling 996 shares during the quarter. Eli Lilly and Company makes up 0.7% of Achmea Investment Management B.V.’s holdings, making the stock its 26th largest holding. Achmea Investment Management B.V.’s holdings in Eli Lilly and Company were worth $45,433,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Tredje AP fonden increased its stake in Eli Lilly and Company by 15.9% during the 4th quarter. Tredje AP fonden now owns 240,123 shares of the company’s stock worth $185,375,000 after purchasing an additional 33,020 shares in the last quarter. Avantax Advisory Services Inc. increased its stake in Eli Lilly and Company by 10.7% during the 4th quarter. Avantax Advisory Services Inc. now owns 51,279 shares of the company’s stock worth $39,587,000 after purchasing an additional 4,937 shares in the last quarter. Essential Planning LLC. increased its stake in Eli Lilly and Company by 6,406.9% during the 4th quarter. Essential Planning LLC. now owns 716,081 shares of the company’s stock worth $593,544,000 after purchasing an additional 705,076 shares in the last quarter. Egerton Capital UK LLP bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $216,917,000. Finally, Liberty Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 11.8% during the 4th quarter. Liberty Wealth Management LLC now owns 1,586 shares of the company’s stock worth $1,224,000 after acquiring an additional 167 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Citigroup decreased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target for the company. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Trading Down 0.2 %

Shares of Eli Lilly and Company stock opened at $822.26 on Thursday. The business has a fifty day simple moving average of $829.78 and a two-hundred day simple moving average of $845.29. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The company has a market capitalization of $779.64 billion, a price-to-earnings ratio of 70.22, a P/E/G ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to buy up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.